Search

OBJECTIVE: To investigate the application and trend of therapeutic drugs in patients with endometrial disease in Beijing, Shanghai and Guangzhou, and to evaluate the application rationality of drugs. METHODS:Prescription data of patients with endometrial disease in Beijing, Shanghai and Guangzhou from 2015 to 2018 were extracted from the hospital prescription analysis cooperation project database, the defined daily dose system (DDDs) and defined daily cost (DDC) were analyzed retrospectively. RESULTS: A total of 21 516 outpatient prescriptions and 58 203 inpatient medical orders were collected form patients with endometrial disease in Beijing, Shanghai and Guangzhou from 2015 to 2018, among which 6 556 prescriptions and medical orders were for conservative treatment of patients with endometrial hyperplasia. Progesterone and gonadotropin drugs were the most used, and the proportion of prescriptions and consumption sum of progesterone and gonadotropin drugs in outpatients were respectively 30. 06% (6 468/21 516) and 27. 43% (1 158 434. 00 yuan/4 223 367. 42 yuan), the proportion of medical orders and consumption sum of progesterone and gonadotropin drugs in inpatients were respectively 0. 35% (202/58 203) and0. 71% (37 206. 70 yuan/5 207 408. 43 yuan), followed by oral contraceptives, levonorgestrel intrauterine birth control system and gonadotropin-releasing hormone agonist. In oral progesterone, DDDs of medroxyprogesterone, medroxyprogesterone, dydrogesterone and progesterone were respectively 735 600. 40, 28 090. 88, 24 127. 00 and 12 857. 00, and DDC were respectively 0. 70, 40. 35, 24. 08 and 37. 42 yuan, and the DDDs were in an increasing trend year by year. In oral contraceptives, the number of case-times with ethinylestradiol cyproterone, drospirenone ethinylestradiol and deoxyprogesterone ethinylestradiol were respectively 260, 139 and 61, and the application of ethinylestradiol cyproterone was more than that of drospirenone ethinylestradiol and deoxyprogesterone ethinylestradiol.Among 6 556 prescriptions and medical orders for conservative treatment of patients with endometrial hyperplasia, 4 909 (74. 88%) were for progesterone and gonadotropin drugs alone. CONCLUSIONS: The outpatient clinic is the main place for clinicians to prescribe progesterone and gonadotropin drugs for patients with endometrial hyperplasia.Prescriptions for endometrial disease are mainly progesterone and gonadotropin drugs for monotherapy, mainly oral progesterone, of which medroxyprogesterone, megestrol, dydrogesterone and progesterone are mostly used with good drug economy, medroxyprogesterone has the lowest DDC. Therefore, by strengthening the standardization of application of progesterone and the economy of drug selection for patients with endometrial disease in outpatients, the rationality of patients’ medication can be continuously improved. [ABSTRACT FROM AUTHOR]